New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 23, 2014
10:02 EDTTEVA, PKY, MNK, HSP, EQR, CTB, BDN, VTR, SLXP, MYL, JEC, GT, ENDP, CBI, ARCP, VRX, PRGO, MW, HST, ESS, DRH, BR, ACTOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Actavis (ACT) initiated with a Buy at Deutsche Bank... American Realty (ARCP) initiated with a Perform at Oppenheimer... Brandywine Realty (BDN) initiated with a Neutral at Mizuho... Broadridge (BR) initiated with an Outperform at Raymond James... Chicago Bridge & Iron (CBI) initiated with a Market Perform at Wells Fargo... Cooper Tire (CTB) initiated with a Neutral at JPMorgan... DiamondRock (DRH) initiated with a Neutral at ISI Group... Endo (ENDP) initiated with a Buy at Deutsche Bank... Equity Residential (EQR) initiated with a Neutral at Mizuho... Essex Property Trust (ESS) initiated with a Buy at Mizuho... Fluor (FLR) initiated with an Outperform at Wells Fargo... Goodyear Tire (GT) initiated with an Overweight at JPMorgan... Hospira (HSP) initiated with a Hold at Deutsche Bank... Host Hotels (HST) initiated with a Neutral at ISI Group... Jacobs Engineering (JEC) initiated with an Outperform at Wells Fargo... Jazz Pharmaceutical initiated with a Buy at Buckingham... Mallinckrodt (MNK) initiated with a Buy at Deutsche Bank... Men's Wearhouse (MW) reinstated with a Buy at Goldman... Mylan (MYL) initiated with a Buy at Deutsche Bank... Parkway Properties (PKY) initiated with a Neutral at Mizuho... Perrigo (PRGO) initiated with a Buy at Deutsche Bank... Salix (SLXP) initiated with a Hold at Deutsche Bank... Teva (TEVA) initiated with a Buy at Deutsche Bank... Valeant (VRX) initiated with a Hold at Deutsche Bank... Ventas (VTR) initiated with a Buy at Mizuho.
News For ACT;ARCP;BDN;BR;CBI;CTB;DRH;ENDP;EQR;ESS;GT;HSP;HST;JEC;MNK;MW;MYL;PKY;PRGO;SLXP;TEVA;VRX;VTR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>
April 8, 2015
07:16 EDTMYL, TEVAMylan one of the cheapest names in Specialty Pharma, says JPMorgan
Subscribe for More Information
06:52 EDTEQREquity Residential initiated with an Outperform at BMO Capital
Subscribe for More Information
06:51 EDTESSEssex Property Trust initiated with a Market Perform at BMO Capital
Subscribe for More Information
06:50 EDTVTRVentas initiated with a Market Perform at BMO Capital
Subscribe for More Information
April 7, 2015
15:24 EDTTEVATeva price target raised to $75 from $64 at BMO Capital
BMO Capital raised its EPS estimates for Teva (TEVA) and increased its price target on the stock to $75 from $64 on account of the expected launch of a treatment for chorea associated with Huntingtonís disease in 3Q16 and a launch of a tardive dyskinesia drug in 3Q17 following the company's deal to buy Auspex (ASPX). The firm maintains its Outperform rating on Teva shares.
15:13 EDTARCPAmerican Realty appoints Hugh Frater as non-executive chairman
Subscribe for More Information
11:02 EDTHSPHospira responds to FDA warning letter
Subscribe for More Information
10:19 EDTMYL, VTRHigh option volume stocks
Subscribe for More Information
09:30 EDTHSPHospira sent FDA warning letter following site inspection
The FDA sent a warning letter to Hospira, dated March 31, following a May 5-9 and 12-13, 2014 inspection of the company's pharmaceutical manufacturing facility. "We have conducted a detailed review of your firmís response dated June 4, 2014 and note that it lacks sufficient corrective actions. We acknowledge receipt of your firmís correspondence dated August 4, 2014, October 2, 2014, December 4, 2014, and February 9, 2015," the FDA states in its letter. Reference Link
07:46 EDTJECJacobs Engineering awarded contract from Texas DOT
Subscribe for More Information
07:32 EDTMYLMylan launches Norethindrone and Ethinyl Estradiol Tablets in U.S.
Subscribe for More Information
April 6, 2015
11:11 EDTARCPOptions with decreasing implied volatility
Options with decreasing implied volatility: BDSI CONN HLSS CTRX DANG ARCP KMX MAC
06:54 EDTVTRVentas to acquire Ardent Medical Services for $1.75B
Subscribe for More Information
06:52 EDTVTRVentas to acquire Ardent Medical Services for $1.75B
06:51 EDTVTRVentas to host conference call
Conference call to discuss plan to spin off post-acute/skilled nursing facility portfolio will be held on April 6 at 8:30 am. Webcast Link
06:36 EDTVTRVentas to acquire Ardent Health Services for $1.75B
Subscribe for More Information
06:33 EDTVTRVentas announces plan to spin off post-acute/skilled nursing facility portfolio
Subscribe for More Information
06:15 EDTCTBSEC accuses two of insider trading in Cooper Tire deal
The Securities and Exchange Commission on Thursday charged two longtime friends who illegally profited from insider trading on news of a proposed acquisition of Cooper Tire and Rubber Company by Apollo Tyres Ltd. In a complaint filed in U.S. district court in Connecticut, the SEC filed fraud charges against Amit Kanodia, of Brookline, Massachusetts, an entrepreneur and private equity investor, and Iftikar Ahmed, of Greenwich, Connecticut, a general partner at a venture capital firm. The SEC named Rakitfi Holdings LLC, a company owned by Ahmed, and Lincoln Charitable Foundation, a supposed charity operated by Kanodia, as relief defendants. The SEC is seeking to have the defendants return their allegedly ill-gotten gains with interest and pay civil monetary penalties.
05:56 EDTTEVATeva battles possible generic Copaxone competitors, Globes reports
A citizen's petition has been filed by Teva with the FDA against possible generic competition to its MS treatment Copaxone beginning in September, Globes reports. The FDA has previously ruled that it was "too early" to discuss the matter. Reference Link
April 5, 2015
14:43 EDTACTActavis seeks FDA approval to market generic version of Gilead's Letairis
Actavis (ACT) on Friday, confirmed that it has filed an Abbreviated New Drug Application with the FDA seeking approval to market Ambrisentan Tablets, 5 mg and 10 mg. Actavis' ANDA product is a generic version of Gilead Science's (GILD) Letairis, which is a treatment for pulmonary arterial hypertension. Gilead Sciences and Royalty Pharma Collection Trust filed suit against Actavis on April 1, in the U.S. District Court for the District of Delaware seeking to prevent Actavis from commercializing its ANDA product prior to the expiration of U.S. Patent number RE42,462. The lawsuit was filed under the provisions of the Hatch-Waxman Act, resulting in a stay of final FDA approval of Actavis' ANDA for up to 30 months from the date the plaintiffs received notice of Actavis' ANDA filing or until final resolution of the matter before the court, whichever occurs sooner, subject to any other exclusivities. Based on available information, Actavis believes it may be a "first applicant" to file an ANDA for the generic version of Letairis and, should its ANDA be approved, may be entitled to 180 days of generic market exclusivity. For the 12 months ending December 31, Letairis had global sales of approximately $595M, according to Gilead.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use